Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools GIST

GIST

Programs, trials, and reported response and survival for gastrointestinal stromal tumor.

Data as of 11.07.2026

All studies

Imatinib

Adjuvant Study 1 (ACOSOG Z9001)

Novartis · Phase 3 · Completed · Enrollment 732

NCT00041197

ArmPopulationDoseEstimandComparatorEfficacy
Imatinib 400 mg for 12 monthsresected primary GIST 3 cm or more400 mgITTplaceborecurrence-free survival hazard ratio vs placebo (interim): 0.4 HR, median follow up 15 monthsrecurrence-free survival hazard ratio vs placebo (updated): 0.72 HR, median follow up 50 months